Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Rafael Holdings, Inc. (RFL)

Rafael Holdings investor deck: Phase 3 last patient visit done, NDA due 2H 2026

Neutral Impact 2 of 5 other Written later

Rafael Holdings furnished a July 2026 investor presentation under Regulation FD, posted on its website from July 8, 2026. The deck says the Phase 3 trial of Trappsol Cyclo completed its last patient last visit in June 2026, with NDA submission and topline data expected in the second half of 2026, and it cites a cash balance of about $30.5 million as of April 30, 2026.

Key points

  • Phase 3 trial of Trappsol Cyclo for Niemann-Pick Disease Type C1 completed last patient last visit in June 2026
  • NDA submission and topline data expected in the second half of 2026
  • Cash balance of about $30.5 million as of April 30, 2026
  • Trial enrolled 104 subjects: 94 in the core study and 10 in the sub-study

The filing

CompanyRafael Holdings, Inc. (RFL)
Form8-K, current report
Filed with the SECJul 8, 2026, 4:45 PM ET
Accession number0001213900-26-076411

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.